Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas nisl neque, tincidunt ut risus ac, pulvinar aliquet orci. Morbi ultricies lacus a purus maximus.

References:

1. Kumar L, Hussain MM, Chethan R, Sahoo RK, Malik PS, Sharma OD, et al; for AIIMS Myeloma Group. Multiple Myeloma: Impact of Time to Transplant on the Outcome. Clin Lymphoma Myeloma Leuk 2022; 22(9):e826-e835.

2. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al; DETERMINATION Investigators. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387(2):132-147.

3. Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22(10):1378-1390.

4. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al; PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2024; 390(4):301-313.

5. Medina-Herrera A, Sarasquete ME, Jiménez C, Puig N, García-Sanz R. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers (Basel) 2023; 15(14):3687.